Answers are grounded in this paper and cite their sources.
Accessing tumor-reactive CD8⁺ T cells in patient blood is essential for non-invasive monitoring of systemic T cell responses and guiding personalized therapies. However, precise functional, molecular, and phenotypic characterization of these cells remains challenging. Here, we identify TIGIT as a functionally validated surrogate marker of tumor-reactive CD8⁺ T cells and define its associated transcriptional program to characterize circulating tumor-reactive CD8⁺ T cells in melanoma patients. We demonstrate that blood TIGIT⁺ CD8⁺ T cells mount robust cytotoxic responses against autologous tumor cells across multiple melanoma patient models, irrespective of PD-1 co-expression. At the clonotype level, TIGIT broadened detection of the circulating tumor-reactive repertoire beyond PD-1 while retaining high specificity. Moreover, circulating TIGIT⁺ CD8⁺ T cell population was closely associated with the intratumoral T cell repertoire and exhibited hallmarks of antigen experience, including effector memory differentiation, a hypomethylated DNA landscape, and increased clonal expansion. Longitudinal profiling of blood samples from melanoma patients undergoing immune checkpoint inhibition revealed an increased frequency of TIGIT⁺ CD8⁺ T cells in clinical responders. Finally, leveraging paired single-cell transcriptomic and TCR data from patient models with identified tumor-reactive clones, we show that the TIGIT-associated transcriptional program enables robust detection of circulating tumor-reactive CD8⁺ T cells. Collectively, our data establish TIGIT⁺ CD8⁺ T cells as a potent reservoir of tumor-reactive T cells in peripheral blood and provide a blood-based framework for accelerating TCR discovery and advancing adoptive cell therapy.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: